Drugs / AMREDOBRESIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02516553 | Jul 2015 → Nov 2021 | nut midline carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMREDOBRESIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3919831 ↗ |
| Known as | BI 894999 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02516553 ↗ |
| Action | Inhibit | “BI 894999 is a novel oral BET inhibitor” PMID 37556913 ↗ Jul 2023 |
| Modality | Small molecule | — CHEMBL3919831 ↗ |
| Route | Oral | “Participants take tablets once daily.” NCT02516553 ↗ |